Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

Multiple Sclerosis Journal

Volumn 19, Issue 6, 2013, Pages 765-774

  Tedeholm, H ^a   Lycke, J ^a   Skoog, B ^a   Lisovskaja, V ^b   Hillert, J ^c   Dahle, C ^d   Fagius, J ^e   Fredrikson, S ^c   Landtblom, A M ^d   Malmestrom C ^a   Martin, C ^f   Piehl, F ^c   Runmarker, B ^a   Stawiarz, L ^c   Vrethem, M ^d   Nerman, O ^b   Andersen, O ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f DANDERYD HOSPITAL   (Sweden)

Author keywords

disease progression; disease severity; Disease modifying drugs; epidemiology; multiple sclerosis; relapsing remitting multiple sclerosis; secondary progressive multiple sclerosis; Sweden; time to progression

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; ONSET AGE; POPULATION RESEARCH; REMISSION; RETROSPECTIVE STUDY; SURVIVAL; EPIDEMIOLOGY; IMMUNOLOGY; KAPLAN MEIER METHOD; MORTALITY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME; TREATMENT OUTCOME;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SWEDEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877597206     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512463764     Document Type: Article

References (36)

1. Amato MP, Ponziani G. A prospective study on the prognosis of multiple sclerosis. Neurol Sci. 2000 ; 21: S831 - S838
2. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003 ; 126: 770-782
3. Kister I, Chamot E, Bacon JH, et al. Trend for decreasing Multiple Sclerosis Severity Scores (MSSS) with increasing calendar year of enrollment into the New York State Multiple Sclerosis Consortium. Mult Scler. 2011 ; 17: 725-733
4. Marrie RA, Cutter G, Tyry T, et al. Changes in the ascertainment of multiple sclerosis. Neurol. 2005 ; 65: 1066-1070
5. Kister I, Chamot E, Cutter G, et al. Increasing age at disability milestones among MS patients in the MSBase Registry. J Neurol Sci. 2012 ; 318: 94-99
6. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000 ; 6: 255-266
7. Rudick RA, Cutter GR, Baier M, et al. Estimating the long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler. 2005 ; 11: 626-634
8. Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurol. 2006 ; 67: 1242-1249
9. Goodin DS, Jones J, Li D, et al. Establishing long-term efficacy in chronic disease: Use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011 ; 6: e22444
10. Daumer M, Neuhaus A, Lederer C, et al. Prognosis of the individual course of disease-Steps in developing a decision support tool for multiple sclerosis. BMC Med Inform Decis Mak. 2007 ; 7: 11
11. McFarland HF, Reingold SC. The future of multiple sclerosis therapies: Redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler. 2005 ; 11: 669-676
12. Veugelers PJ, Fisk JD, Brown MG, et al. Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: A longitudinal population-based evaluation. Mult Scler. 2009 ; 15: 1286-1294
13. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007 ; 61: 300-306
14. Conway DS, Miller DM, O'Brien RG, et al. Long-term benefit of multiple sclerosis treatment: An investigation using a novel data collection technique. Mult Scler. 2012 ;:
15. Gout O. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2008 ; 63: 126
16. Renoux C, Suissa S. Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol. 2008 ; 64: 109-110
17. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA. 2012 ; 308: 247-256
18. Runmarker B, Andersson C, Oden A, et al. Prediction of outcome in multiple sclerosis based on multivariate models. J Neurol. 1994 ; 241: 597-604
19. Royston P. Explained variation for survival models. Stata J. 2006 ; 6: 83-96
20. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 ; 116: 117-134
21. Marrie R, Horwitz R, Cutter G, et al. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008 ; 14: 1091-1098
22. Pittock SJ, Mayr WT, McClelland RL, et al. Disability profile of MS did not change over 10 years in a population-based prevalence cohort. Neurol. 2004 ; 62: 601-606
23. Shirani A, Zhao Y, Kingwell E, et al. Temporal trends of disability progression in multiple sclerosis: Findings from British Columbia, Canada (1975-2009). Mult Scler. 2012 ; 18: 442-450
24. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurol. 1996 ; 46: 907-911
25. Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry. 2000 ; 68: 450-457
26. Trojano M. Reply to Oliver Gout. Ann Neurol. 2008 ; 63: 126-127
27. Beck CA. Selection bias in observational studies: Out of control?. Neurol. 2009 ; 72: 108-109
28. Renoux C. Natural history of multiple sclerosis: Long-term prognostic factors. Neurol Clin. 2011 ; 29: 293-308
29. Phadke JG. Clinical aspects of multiple sclerosis in North-East Scotland with particular reference to its course and prognosis. Brain. 1990 ; 113: 1597-1628
30. Levic ZM, Dujmovic I, Pekmezovic T, et al. Prognostic factors for survival in multiple sclerosis. Mult Scler. 1999 ; 5: 171-178
31. Scott TF, Schramke CJ, Novero J, et al. Short-term prognosis in early relapsing-remitting multiple sclerosis. Neurol. 2000 ; 55: 689-693
32. Langer-Gould A, Popat RA, Huang SM, et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: A systematic review. Arch Neurol. 2006 ; 63: 1686-1691
33. Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010 ; 133: 1900-1913
34. Yamout B, Itani S, Arabi A, et al. Prognostic factors of multiple sclerosis in Lebanon. Int J Neurosci. 2010 ; 120: 206-210
35. Andersen O. Restricted dissemination of clinically defined attacks in an MS incidence material. Acta Neurol Scand Suppl. 1980 ; 77: 1-70
36. Uitdehaag BM, Kappos L, Bauer L, et al. Discrepancies in the interpretation of clinical symptoms and signs in the diagnosis of multiple sclerosis. A proposal for standardization. Mult Scler. 2005 ; 11: 227-231